Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum

Area of Science:

• Gynecologic Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Primary vaginal cancer is a rare gynecologic malignancy.
• Curative treatment often involves a combination of radiation and chemotherapy.
• Optimizing treatment protocols is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the feasibility of concurrent weekly Cis-platinum chemoradiation (CRT) for primary vaginal cancer.
• To evaluate the efficacy and toxicity of this treatment approach.

Main Methods:

• Retrospective review of 12 primary vaginal cancer patients treated with curative intent.
• Concurrent weekly Cis-platinum chemotherapy (40 mg/m²) with pelvic external beam radiotherapy (EBRT).
• Followed by brachytherapy (BT) (interstitial or intracavitary).

Main Results:

• Median follow-up was 50 months.
• 5-year survival rates: Overall 66%, Progression-free 75%, Locoregional progression-free 92%.
• Late toxicity requiring surgery occurred in 17% of patients.

Conclusions:

• Concurrent weekly Cis-platinum CRT is a feasible treatment for primary vaginal cancer.
• This approach demonstrates excellent local control.
• The toxicity profile is acceptable, supporting its use in clinical practice.